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Abstract (limit 250 words) 21 
Human cytomegalovirus (HCMV) infection and periodic re-activation is generally well 22 
controlled by the HCMV-specific T cell response in healthy people.  While the CD8+ T 23 
cell response to HCMV has been extensively studied, the HCMV-specific CD4+ T cell 24 
effector response is not as well understood, especially in the context of direct 25 
interactions with HCMV infected cells.  We screened the IFNγ and IL-10 response to 6 26 
HCMV peptide pools (selected as the most frequently responded to in our previous 27 
studies: pp65, pp71, IE1, IE2, gB and US3) in 84 donors, aged 23 – 74 years.  28 
Predominantly the HCMV specific CD4+ T cell response to pp65, IE1, IE2 and gB was 29 
Th1 biased with neither loss nor accumulation of these responses with increasing age.  30 
A larger proportion of donors produced an IL-10 response to pp71 and US3 but the 31 
IFNγ response was still dominant.  CD4+ T cells specific to the HCMV proteins studied 32 
were predominantly effector memory cells and produced both cytotoxic (CD107a 33 
expression) and cytokine (MIP1β secretion) effector responses.    Importantly, when we 34 
measured the CD4+ T cell response to CMV infected Dendritic Cells in vitro, we 35 
observed that the CD4+ T cells produced a range of cytotoxic and secretory effector 36 
functions, despite the presence of CMV encoded immune evasion molecules.   CD4+ T 37 
cell responses to HCMV infected dendritic cells were sufficient to control the 38 
dissemination of virus in an in vitro assay.  Together the results show that HCMV-39 
specific CD4+ T cell responses are highly functional even from elderly individuals and 40 
are directly anti-viral. 41 
 42 
  43 
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Importance (limit 150 words) (non-technical explanation of significance) 44 
Human cytomegalovirus (HCMV) infection is carried for a lifetime and in healthy people 45 
is kept under control by the immune system.  HCMV has evolved many mechanisms to 46 
evade the immune response, possibly explaining why the virus is never eliminated 47 
during the hosts’ lifetime.  Dysfunction of immune cells associated with long-term 48 
carriage of HCMV has been linked with poor responses to new pathogens and vaccines 49 
when older.  In this study we have investigated the response of a subset of immune 50 
cells (CD4+ T cell) to HCMV proteins in healthy donors of all ages demonstrating that 51 
the functionality of the CD4+ T cells is maintained.  We have also shown that CD4+ T 52 
cells produce effector functions in response to HCMV infected cells and can prevent 53 
virus spread.  Our work demonstrates that these HCMV-specific immune cells retain 54 
many important functions and help to prevent deleterious HCMV disease in healthy 55 
older people.  56 
 57 
  58 
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Introduction 59 
 60 
Human cytomegalovirus (HCMV), a β herpes virus, is a ubiquitous pathogen found 61 
worldwide (1).   Infection with this virus is characterised by the establishment of life-long 62 
persistence, in part, because HCMV can establish a latent infection in bone marrow 63 
stem cells and cells of the myeloid lineage (2).  Infection with HCMV is asymptomatic for 64 
most individuals, however when the immune system is compromised by other infections 65 
or treatments (such as HIV/AIDS or transplant patients) or is immature (such as the 66 
foetus in utero), it can cause significant morbidity and mortality (3, 4).  During primary 67 
infection with HCMV both the innate and adaptive branches of the immune system 68 
respond (1, 3, 4) and evidence from mouse studies has shown the important role CD4+ 69 
T cells play in controlling CMV infection (reviewed in(5)).  Studies in humans undergoing 70 
bone marrow, stem cell and solid organ transplantations have confirmed the role CMV 71 
specific CD4+ T cells have in abrogating reactivating infection (6-9) and studies in 72 
primary infection in adults have also clearly shown the requirement for functional CD4+ 73 
T cells in the resolution of symptomatic disease (10-12).  In healthy subjects, persistent 74 
shedding of the virus into urine and saliva is associated with a lack of CD4+ T cell 75 
response directed towards CMV, which is particularly observed in CMV infection in 76 
young children (13). 77 
 78 
Identification of HCMV specific CD4+ T cells has mainly been by intracellular cytokine 79 
production, predominantly measuring IFNγ production in response to stimulation, these 80 
studies have shown large responses to both pp65 and IE proteins of the virus (work 81 
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summarised in (3, 4, 14)).  CD4+ T cell responses specific to the gB protein (UL55) (15, 82 
16) have also been described.  Analysis of the CD4+ T cell response to the whole 83 
HCMV proteome also identified numerous responses towards many different ORFs, this 84 
study suggested that an individual donor, has on average, CD4+ T cells specific to 12 85 
different HCMV ORFs (17).  A meta-analysis of published studies has identified the 10 86 
most frequently recognised HCMV ORFs by CD4+ T cells these were TRL14, UL16, 87 
UL55, UL83, UL85, US3, UL25, US18, UL45 and UL32 (3).  Many more studies have 88 
investigated the frequency, phenotype and function of CD4+ T cells specific to HCMV 89 
using whole viral lysate stimulation (10, 12, 18-22), these have estimated that up to 5% 90 
(19) of the CD4+ T cell peripheral blood compartment can be directed towards the virus.  91 
This dominance of the CD4+ T cell compartment has also been observed as high as 92 
10% when the whole virus proteome was used (17).  Additionally, the application of 93 
MHC Class II tetramers has also observed as high as 5% of the CD4+ T cell pool 94 
responding to one HCMV gB protein Class II epitope (23).  95 
 96 
CMV specific CD4+ T cells, mainly identified by IFNγ secretion following stimulation with 97 
whole CMV viral lysate, have been shown to be enriched for phenotypes linked to 98 
terminal differentiation and dysfunctional responses characterised by CD45RA re-99 
expression (11, 21, 24) and the loss of expression of the co-stimulatory molecules 100 
CD28 and CD27 (10, 20, 22, 25, 26) and these cells have also been associated with a 101 
loss of cytokine secretion ability and limited proliferation capacity (19, 22, 27).  These 102 
previous studies have led to the hypothesis that enlarged “dysfunctional” HCMV specific 103 
CD4+ T cell populations accumulate with age and that these HCMV induced changes 104 
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may become detrimental to individuals (27-29).   However, it is noteworthy that in other 105 
studies HCMV specific CD4+ T cells have also been shown to produce a range of anti-106 
viral effector functions including production of multiple anti-viral cytokines and to have 107 
cytolytic effector functions (30-32), functional CMV specific CD4+ T cells were also 108 
confirmed in the Rhesus Macaque ageing model (33) and murine ageing models 109 
looking at latent MCMV infection (34, 35).  The poly-functional capacity of CMV specific 110 
CD4+ T cells were also maintained in the more differentiated memory phenotypes seen 111 
in older CMV sero-positive donors (20, 21, 26, 30, 36).   A number of longitudinal 112 
studies have linked HCMV sero-positivity and the associated changes to the T cell 113 
repertoire with older individuals being more susceptible to infections, responding poorly 114 
to vaccinations and increased risk of mortality compared to age matched HCMV sero-115 
negative individuals (systematically reviewed in (37)).  However, a poor response to 116 
influenza vaccination in CMV sero-positive older people is not seen in all studies, and 117 
there is evidence that certainly in the young being CMV positive can be beneficial in 118 
mediating responses to vaccination (34).  There is a body of evidence that over the age 119 
of 65 there are changes to the immune response that increase morbidity and mortality in 120 
responses to infection and autoimmune disease (38, 39).   Analysis of a number of large 121 
population cohorts recruited for cancer, dementia and nutritional studies in the UK and 122 
USA have shown a significant association between CMV sero-positivity and mortality 123 
from cardiovascular related disease (40-43).  Despite these observations older CMV 124 
sero-positive individuals do not appear to suffer from overt HCMV disease from 125 
reactivating virus or super infection, suggesting that the HCMV specific T cells retain the 126 
ability to control the virus (44).  There is also evidence that does not support the role of 127 
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CMV sero-positivity in causing a decline in immune responses to novel infections in the 128 
elderly (45, 46).   129 
 130 
Many studies investigating the functionality of CD4+ T cell responses to HCMV infection 131 
have relied on using whole viral lysate or focusing only on the seemingly immune-132 
dominant pp65 or gB viral proteins as stimuli.   However, few studies have interrogated 133 
the different contributions of the many HCMV proteins that CD4+ T cells respond to 134 
(17), to the functional activity of the CMV specific CD4+ T cell response.  Previously, we 135 
have shown that CD4+T cell responses to the limited number of proteins expressed 136 
during HCMV latency produce the immunosuppressive cytokine IL-10 which differed 137 
from the CD4+ T cell response to HCMV proteins only expressed during lytic infection 138 
(47).   Using only peptide pools or viral lysate also ignores the impact of the large 139 
number of immune evasion molecules encoded by the virus during active lytic infection 140 
on the immune response and the effector functions of CD4+ T cells.   We have 141 
measured the effect of donor age on CD4+ T cell responses to 6 HCMV ORF encoded 142 
proteins (UL83 (pp65), UL82 (pp71), UL123 (IE1), UL122 (IE2), UL55 (gB) and US3), 143 
measuring IFNγ and IL-10 responses by Fluorospot.   We did not observe an 144 
accumulation of CD4+ T cell IFNγ responses to the 6 HCMV proteins with increasing 145 
donor age and there were limited IL-10 responses to pp65, gB, IE1 and IE2 stimulation 146 
within this donor cohort.  The IL-10 response to pp71 and US3 stimulation was more 147 
frequently observed however the magnitude of the response was maintained regardless 148 
of donor age.  CD4+ T cells responding to the 6 HCMV proteins examined had both 149 
cytotoxic and inflammatory effector functions and were mostly effector memory T cells, 150 
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with pp65 specific CD4+ T cells exhibiting a more differentiated phenotype than the 151 
other HCMV specific CD4+ T cells.   We next assessed the effector capacity of CD4+ T 152 
cells when stimulated by HCMV infected moDCs, CMV specific CD4+ T cells isolated 153 
directly ex-vivo produced both cytotoxic and secretory effector functions.  Using an in 154 
vitro model of lytic CMV infection, where moDCs were infected with CMV for 7 days 155 
prior to co-incubation with CD4+ T cells, we demonstrated that CMV specific CD4+ T 156 
cells are able to prevent viral dissemination.  This study shows that healthy people of all 157 
ages can maintain highly functional HCMV-specific CD4+ T cell responses that can 158 
respond to HCMV infected cells. 159 
  160 
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Materials and Methods 161 
 162 
Ethics and Donor Cohort information 163 
Healthy CMV sero-positive and negative donors were recruited locally with ethical 164 
approval from the Addenbrookes National Health Service Hospital Trust institutional 165 
review board (Cambridge Research Ethics Committee); informed written consent was 166 
obtained from all volunteers in accordance with the Declaration of Helsinki (LREC 167 
97/092).   22 HCMV sero-positive donors (5/17 Female/Male) aged 23 – 77 years were 168 
recruited.  A second healthy donor cohort was recruited from the National Institute of 169 
Health Research (NIHR) Cambridge BioResource.  Ethical approval was obtained from 170 
University of Cambridge Human Biology Research Ethics Committee.  Informed written 171 
consent was obtained from all donors in accordance with the Declaration of Helsinki 172 
(HBREC.2014.07).   A cohort of 84 HCMV sero-positive donors (48/36 Female/Male) 173 
aged 23 – 74 years and 24 sero-negative donors (14/10 Female/Male) aged 29 – 78 174 
years were included in this study.  CMV sero-status of all donors was confirmed by 175 
serological assessment of CMV IgG levels using Captia CMV IgG EIA test (Trinity 176 
Biotech, Ireland) following the manufacturer’s instructions. 177 
 178 
Peripheral Blood Mononuclear cell isolation 179 
Peripheral blood mononuclear cells (PBMC) were isolated from heparinised blood 180 
samples using Lymphoprep (Axis-shield, Alere Ltd, Stockport, UK) density gradient 181 
centrifugation.   PBMC were either used fresh or frozen in a 10% DMSO (Sigma Aldrich, 182 
Poole, UK) and 90% Fetal Bovine Serum (FBS) (Gibco – Thermofisher Scientific, 183 
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Paisley, UK) solution at a high cell concentration.  Frozen PBMC were resuscitated 184 
before use in pre-warmed serum-free media in the presence of 10U/ml DNase I (Roche 185 
Diagnostics Ltd, Burgess Hill, UK) or Benzonase nuclease (Millipore, Watford, UK), 186 
followed by 1 hour incubation in warmed serum-free media and DNase I or Benzonase 187 
nuclease at 37°C then further rested in X-VIVO 15 media (Lonza, Slough, UK) at 37°C 188 
before use in subsequent assays. 189 
 190 
HCMV ORF peptide mixes 191 
10 HCMV ORFs (UL28, UL48, UL55 (gB), UL82 (pp71), UL99, UL122 (IE2), UL123 192 
(IE1), US3, US29 and US32) were selected and consecutive 15mer peptides 193 
overlapping by 10 amino acid libraries were synthesised by ProImmune PEPScreen 194 
(Oxford, UK) from sequences detailed in the Sylwester et. al. study (17).  A UL83 (pp65) 195 
ORF 15mer peptide library was synthesised by JPT Peptide Technologies GmbH 196 
(Berlin, Germany).  The individual lyophilised peptides from each ORF library were 197 
reconstituted and used as previously described (48).   198 
 199 
Virus  200 
HCMV strain TB40/e UL32-GFP (gift of Christian Sinzger, Universitätsklinikum Ulm 201 
Institut für Virologie, Germany) was used in this study.  The infectious titre of the 202 
endothelial tropic passaged strain was determined using ARPE-19 cells; the pfu/ml 203 
(plaque forming units) was used to calculate the Multiplicity of Infection used to infect 204 
monocyte derived dendritic cells.   Ultra-violet (UV) treatment of TB40/e UL32-GFP was 205 
performed for 60 minutes to inactivate the virus stock.    206 
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 207 
Dual FLUOROSPOT assays 208 
PBMC were depleted of CD8+ T cells by MACS using anti-CD8+ direct beads (Miltenyi 209 
Biotech), according to manufacturer's instructions and separated on either LS columns 210 
with VarioMACS stand (Miltenyi Biotech) or using an AutoMACS Pro (Miltenyi Biotech). 211 
Efficiency of depletion was determined by staining cells with a CD3-FITC, CD4-PE and 212 
CD8-PerCPCy5.5 antibody mix (all BioLegend) and analysed by flow cytometry. 213 
Depletions performed in this manner resulted in 0.2 – 4.3% residual CD8+ T cells 214 
(n=40).  Triplicate wells of 2 x 105 CD8+ T cell depleted PBMC suspended in X-VIVO 15 215 
supplemented with 5% Human AB serum (Sigma Aldrich) were incubated in pre-coated 216 
Fluorospot plates (Human IFNγ and IL-10 FLUOROSPOT (Mabtech AB, Nacka Strand, 217 
Sweden) ) with ORF mix peptides (final peptide concentration 2µg/ml/peptide) and an 218 
unstimulated and positive control mix (containing anti-CD3 antibody (αCD3) (Mabtech 219 
AB), Staphylococcus Enterotoxin B (SEB), Phytohaemagglutinin (PHA), Pokeweed 220 
Mitogen (PWM) and Lipopolysaccharide (LPS) (all Sigma Aldrich)) at 37ºC in a 221 
humidified CO2  atmosphere for 48 hours.   The cells and medium were decanted from 222 
the plate and the assay developed following the manufacturer’s instructions.  Developed 223 
plates were read using an AID iSpot reader (Autoimmun Diagnostika (AID) GmbH, 224 
Strassberg, Germany) and counted using EliSpot v7 software (Autoimmun Diagnostika).  225 
The positive response cut-off for IFNγ and the IL-10 responses was determined by 226 
comparing the distribution of the responses from HCMV sero-positive and sero-negative 227 
donors to all HCMV ORFs and the positive control response after background 228 
correction.  This analysis determined that the positive response for IFNγ was greater 229 
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than 100 sfu/million (spot forming units per million cells) (Fig. 1B) and for IL-10 was 230 
greater than 50 sfu/million (Fig. 2A).    231 
 232 
Measurement of Degranulation, cytokine secretion and phenotyping of antigen 233 
specific CD4+ T cells 234 
2.5 x 106 PBMC suspended in X-VIVO 15 + 5% Human AB serum were stimulated with 235 
ORF peptide mixes in the presence of CD107a Alexa fluor 647 (BioLegend), 236 
unstimulated or Positive Control mix (SEB, αCD3, PHA, PWM and LPS) for one hour 237 
and then 5µg/ml Brefeldin A and 2µM Monensin (both BioLegend) were added and 238 
incubated overnight at 37ºC in a humidified CO2  atmosphere.  Cells were then washed, 239 
stained with a combination of surface antibodies including CD3 Brilliant Violet 650, 240 
CD45RA PE-Cy7, CD27 APC-eFluor 780 (eBioscience), CD14 and CD19 FITC – dump 241 
channel (eBioscience) and LIVE/DEAD Fixable Yellow Dead cell stain (Invitrogen) at 242 
4ºC.  Cells were fixed and permeabilised using FIX&PERM (Nordic-MuBio, Susteren, 243 
Holland) and stained intracellularly with CD69 Pacific Blue, 4-1BB PE-Cy5, CD8 244 
AlexaFluor 700, CD4 PE Dazzle (BioLegend), CD40L PerCPeFluor 710 (eBioscience) 245 
and MIP-1β PE (BD Biosciences) at 4ºC in the dark.  Samples were washed and fixed 246 
in a final 1% paraformaldehyde solution and acquired on a BD LSR Fortessa cytometer 247 
using FACSdiva software.  Data was analysed using FlowJo software, antigen specific 248 
CD4+ T cell populations were identified as CD40L+ and CD69high above the background 249 
expression observed in the unstimulated control following elimination of doublets, 250 
removal of monocytes and B cells and dead cells from the analysed population 251 
(example of the CD40L+ and CD69high expression is shown in Fig. 3A), CD69 252 
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expression is lower due to the overnight incubation as opposed to 6hrs, which is why a 253 
CD69high criteria was used to identify the activated cell populations.  The levels of 254 
CD107a staining was set based on the expression measured in activated CD8+ T cells 255 
compared to unstimulated cells for each donor, the positive control sample verified the 256 
expression of the activation markers, CD107a and MIP1β for each donor.  257 
 258 
Measurement of Poly-functional T cell responses to HCMV infected dendritic 259 
cells. 260 
Monocytes were isolated from donor PBMC by MACS using anti-CD14+ direct beads 261 
(Miltenyi Biotech), according to manufacturer's instructions and separated on LS 262 
columns with VarioMACS system.  Purified monocytes were adhered to a 48 well tissue 263 
culture plate at 0.3 x 106 cells per well density and then incubated in X-VIVO 15 264 
supplemented with 2.5mM L-Glutamine (Sigma Aldrich) and 1000 IU/ml IL-4 and 1000 265 
IU/ml GM-CSF (Miltenyi Biotec) for 6 days at 37°C in a humidified CO2 atmosphere.  266 
The differentiated monocytes were matured by exchanging media for X-VIVO 15 267 
supplemented with 2.5mM L-Glutamine and 50ng/ml Lipopolysaccharide (LPS) for 24 268 
hours.  The dendritic cells (moDCs) were then infected with HCMV strain TB40\e-UL32-269 
GFP at an MOI of 0.1 or the equivalent amount of UV-virus for 3 hours in L-glutamine 270 
supplemented X-VIVO 15.  Media was then replaced and the infected cells were 271 
incubated in fresh supplemented X-VIVO 15 for 7 days at 37°C in a humidified CO2 272 
atmosphere.  Infection was confirmed by observation of GFP expression in dendritic 273 
cells by fluorescent microscopy compared to mock and UV-virus treatment and qRT-274 
PCR.  CD4+ T cells were purified from defrosted autologous PBMC by MACS using 275 
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anti-CD4+ beads following the manufacturer’s instruction using LS columns and 276 
VarioMACS.    0.5 x 106 CD4+ T cells suspended in X-VIVO 15 + L-glutamine were 277 
added to each well of uninfected, infected, UV infected, positive control mix pulsed and 278 
pp65 and gB proteins pulsed moDCs in the presence of CD107a Alexa fluor 647 279 
(BioLegend) for one hour and then 5µg/ml Brefeldin A and 2µM Monensin (both 280 
BioLegend) were added and incubated overnight at 37ºC in a humidified CO2 281 
atmosphere.  Cells were harvested, washed and stained with a combination of surface 282 
antibodies; CD45RA PE-Cy7, CD27 APC-eFluor 780 (eBioscience), CD3 Brilliant Violet 283 
650, CD57 PE-Dazzle, CD28 Alexa Fluor 700, CD14 and CD19 Brilliant Violet 510 284 
(BioLegend) and LIVE/DEAD Fixable Aqua Dead cell stain (Invitrogen) – dump channel 285 
at 4ºC.  Cells were fixed and permeabilised using FIX&PERM and stained intracellularly 286 
with CD69 Pacific Blue, 4-1BB PE-Cy5, CD8 Brilliant Violet 570, CD4 Brilliant Violet 287 
605, Granzyme A FITC (BioLegend), Granzyme B FITC (Miltenyi Biotec), CD40L 288 
PerCPeFluor 710 (eBioscience), IFNγ Brilliant Violet 786 and MIP-1β PE (BD 289 
Biosciences) at 4ºC in the dark.  Samples were washed and fixed in a final 1% 290 
paraformaldehyde solution and acquired on a BD LSR Fortessa cytometer using 291 
FACSdiva software.  Data was analysed using FlowJo software, CD4+ T cells were 292 
identified following elimination of doublets, removal of monocytes and B cells and dead 293 
cells from the analysed population.  Antigen specific CD4+ T cell populations were 294 
identified by the expression of CD40L and 4-1BB above the background expression 295 
observed in the unstimulated sample.  The percentage of antigen specific CD4+ T cells 296 
producing combinations of the following functional markers CD107a, Granzymes A and 297 
B, IFNγ, MIP1β above background were identified (gating of populations was 298 
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determined by the use of Fluorescence Minus One samples and the unstimulated 299 
control).   300 
 301 
Measurement of viral dissemination control by CD4+ T cells. 302 
Monocytes were isolated and differentiated and matured to moDCs in 96 well plates at a 303 
density of 0.1x 106 cells per well, as described in the previous section.  The moDC’s 304 
were then infected with HCMV strain TB40\e-UL32-GFP at an MOI of 0.007 or the 305 
equivalent amount of UV-virus for 3 hours in L-glutamine supplemented X-VIVO 15.  306 
Media was then replaced and the infected cells were incubated in fresh supplemented 307 
X-VIVO 15 for 7 days at 37°C in a humidified CO2 atmosphere.  Infection was confirmed 308 
by observation of GFP expression in moDCs by fluorescent microscopy compared to 309 
mock and UV-virus treatment wells.    Autologous CD4+ T cells were purified from 310 
frozen PBMC as described and then added to the wells with infected moDCs at a range 311 
of E:T ratios (1.2:1, 0.6:1 and 0.3:1) in supplemented X-VIVO 15.  The CD4+ T cells 312 
were co-incubated with infected moDCs, after 7 days indicator dermal fibroblasts were 313 
added to moDCs monolayer following removal of the well supernatant and non-adherent 314 
cells.  The fibroblast co-culture was maintained in DMEM (Gibco) supplemented with 315 
20% FBS (Gibco) for up to 21 days at 37°C in a humidified CO2 atmosphere.  The 316 
spread of TB40\e-UL32-GFP in to fibroblasts after 21 days was measured by flow 317 
cytometry acquisition on a BD Accuri C6 flow cytometer following fibroblast harvest with 318 
trypsin and fixing with 2% PFA.    319 
 320 
Statistics 321 
 o
n
 M
arch 14, 2017 by M
EDICAL RESEARCH CO
UNCL - UK SBS
http://jvi.asm.org/
D
ow
nloaded from
 
Page 16 of 52 
 
Statistical analysis was performed using GraphPad Prism version 6.00 for Windows 322 
(GraphPad Software, San Diego, CA, USA). The correlation between age and the T cell 323 
response to CMV was assessed by Spearman rank correlation for non-normally 324 
distributed data.  CD107a, MIP-1β and memory phenotype peptide specific analyses 325 
were compared using a 1 way ANOVA Kruskall-Wallis test with post hoc Dunn’s 326 
multiple comparisons and Wilcoxon matched ranks paired test.  In the cases of 327 
repeated analyses of the same donor cohort results were only considered significant if 328 
p≤0.01.    329 
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Results 330 
 331 
The magnitude of the HCMV specific CD4+ T cell response to 6 different HCMV 332 
ORF encoded proteins is maintained in older donors. 333 
Previous work investigating the HCMV specific CD4+ T cell response, using whole viral 334 
lysate as the stimulus, has shown that the frequency of the HCMV specific CD4+ T cell 335 
response increases with donor age (19, 21, 22) by measuring IFNγ production by intra-336 
cellular flow cytometry methods.    In order to measure the CD4+ T cell response to 337 
individual HCMV  proteins we performed an initial screen of the CD4+ T cell response to 338 
11 HCMV proteins using pools of overlapping peptides to each HCMV protein, in a 339 
small cohort of 18 sero-positive and 4 sero-negative donors.  The 11 selected HCMV 340 
protein peptide pools  included the highest frequency CD4+ T cell responses previously 341 
measured in a whole proteome screen (17), measurement of the frequency of the CD4+ 342 
T cell response to the selected HCMV proteins was performed by IFNγ ELISPOT assay.   343 
Using 100 spot forming units per million cells (sfu/million) as the positive response cut 344 
off for CD4+ T cell responses we ranked the HCMV proteins  according to the number 345 
of responding donors (Fig. 1A).  This ranking enabled identification of the HCMV 346 
proteins gB, pp71, pp65, IE1, IE2 and US3 as being the most commonly responded to 347 
peptide pools in our donor cohort.      348 
 349 
In order to assess whether the frequency of CD4+ T cell responses to different HCMV 350 
proteins change with increasing donor age, we recruited a large CMV sero-positive 351 
donor cohort (n=84) aged 23 – 74 years and also 13 CMV sero-negative donors aged 352 
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37 – 72 years to act as background response controls.  We measured the frequency of 353 
the CD4+ T cell IFNγ response to the 6 highest ranked HCMV encoded proteins 354 
detailed in Fig. 1A, using an IFNγ Fluorospot assay.  The results from the entire donor 355 
cohort for all 6 HCMV proteins and the Positive control are summarised (Fig. 1B). A 356 
positive response threshold of 100 sfu/million was determined as being above the 357 
distribution of any responses measured in the sero-negative cohort to each HCMV 358 
peptide pool, whilst below the response of both sero-positive and negative donors to the 359 
positive control,  the threshold is indicated on the graph with negative responses falling 360 
below the line.  The proportion of the donor cohort responding to each protein are 361 
shown on the graph, a majority of the sero-positive donor cohort responded to all six 362 
proteins studied, with 91.9% of donors generating a positive response to pp65, 70.6%, 363 
69.8%, 65.1%, 56.5% and 52.3% of donors responding to gB, IE2, pp71, US3 and IE1 364 
CMV peptide pools respectively.   Analysis of the frequency of the sero-positive cohort 365 
responding to 1 or more CMV proteins revealed that all donors made a response to at 366 
least 1 of 6 HCMV proteins and 63.1% of donors examined produced an IFNγ response 367 
to 4 or more proteins (Fig. 1C).   368 
 369 
To assess whether donor age had an impact on the frequency of the CD4+ T cell 370 
response to HCMV within this cohort, the sum of the IFNγ responses to all 6 HCMV 371 
proteins for each donor with respect to age was analysed (Fig. 1D), overall there was no 372 
significant change in the magnitude of the response as donor age increased (Spearman 373 
rank correlation).    The magnitude of the donor responses to each of the 6 HCMV 374 
proteins is also illustrated individually for sero-positive donors (Fig. 1E – 1J).  Spearman 375 
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rank correlation tests of the data showed that the relationship between magnitude of 376 
HCMV protein response and age was not significant and the spearman r values for 377 
each ORF (indicated on each graph) are all close to zero for pp65, to correct for 378 
repeated measures results were only considered significant if p≤0.01.   These results 379 
suggest that there is no obvious change in the size of the response to these HCMV 380 
proteins with increasing age.       381 
 382 
CD4+ T cells specific for HCMV ORFs expressed during lytic infection 383 
predominantly have a Th1 cytokine profile. 384 
CD4+ T cells can be characterised by the expression of certain transcription factors and 385 
the cytokines they secrete into different T helper cell populations (49).  We have 386 
previously shown that CD4+ T cells specific to the HCMV ORF encoded proteins UL138 387 
and LUNA have the capacity to secrete the immunomodulatory cytokine IL-10, as well 388 
as having distinct UL138 and LUNA specific CD4+ T cell populations able to secrete 389 
IFNγ, a Th1 defined cytokine (47).  Others have identified CMV specific CD4+ T cells 390 
which secrete IL-10 and their experiments suggested the generation of iTreg cells 391 
specific for HCMV (pp65 and IE ORFs) was related to frequent exposure to CMV 392 
antigen (50).  This suggests that an older CMV seropositive donor may have an 393 
increased numbers of CD4+ T cells secreting IL-10 following CMV stimulation due to 394 
potentially being exposed to the viral antigens for a longer time period.   We measured 395 
the ability of CD4+ T cells to secrete IL-10 and or IFNγ in response to the 6 HCMV 396 
proteins using a dual fluorospot method in 59 sero-positive donors and 8 sero-negative 397 
donors.  We assessed the IL-10 responses of the donor cohort to the 6 HCMV proteins 398 
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analysed and the positive control alone and used the distribution of the response from 399 
the sero-negative cohort to the 6 HCMV protein peptide pools and Positive control to 400 
derive a positive response threshold for IL-10 responses as 50 sfu/million (line shown 401 
on graph in Fig. 2A). The proportion of donors responding above the positive cut-off for 402 
each HCMV protein are also shown, the US3 and pp71 proteins produced an IL-10 403 
response from 44.1% of the cohort, 28.8% responded to pp65, 25.4% to IE2, 20.3% to 404 
IE1 and 15.3% responding to gB.  Confirming the reduced number of IL-10 responses to 405 
the 6 HCMV proteins in this cohort the number of proteins that triggered an IL-10 406 
response above the positive threshold for each donor were analysed, 40.7% of the 407 
cohort did not make an IL-10 response to any of these 6 HCMV proteins (Fig. 2B), no 408 
donor produced an IL-10 response to all 6 proteins in comparison to 20.2% of donors 409 
producing an IFNγ response to all 6 proteins analysed (Fig. 1C).   410 
 411 
The fluorospot technology used allowed the simultaneous assessment of the IFNγ and 412 
IL-10 responses to each HCMV protein, enabling the contribution of IFNγ and IL-10 413 
secretion to the overall response for each donor to be assessed.  The data is 414 
summarised (Fig. 2C – 2H) for the entire sero-positive cohort, only donors that 415 
responded above the positive threshold cut-off for either IFNγ or IL-10 are shown.  For 416 
each donor the size of the IFNγ (grey bar) and IL-10 (clear bar) response in sfu/million 417 
is shown in increasing donor age order along the x-axis, the rarely observed cell 418 
population secreting both IFNγ and IL-10 are indicated by a red bar.  The data shows 419 
that overall the majority of the T cells produce IFNγ (grey bars) and that for pp65, IE1, 420 
gB and IE2 the IL-10 responses are limited.  The combined IFNγ and IL-10 graphs for 421 
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pp71 and US3 clearly show more IL-10 white bars for each donor with no impact on the 422 
frequency with increasing donor age, however the IFNγ response (grey bars) still 423 
predominates for the majority of the donors analysed.  Spearman rank correlation of 424 
age with the magnitude of the IL-10 response to the 6 HCMV ORFs for the donor cohort 425 
revealed that there was a significant decline in IL-10 production in response to IE1 426 
stimulation (rs= -0.4185, p=0.01), the IL-10 response to the other 5 ORFs did not reveal 427 
any significant changes in magnitude with increasing donor age.   428 
 429 
HCMV specific CD4+ T cells have a predominantly effector memory phenotype 430 
and cytotoxic capacity 431 
We and others have previously reported that CMV specific CD4+ T cells can have direct 432 
effector functions both cytotoxic and by secreting inflammatory cytokines (16, 24, 26, 433 
30, 47).  To examine the functional capacity of CD4+ T cells specific to the 6 different 434 
HCMV proteins studied here, we determined CD107a expression, a well-defined marker 435 
of degranulation and indicative of cytotoxic capacity in CD4+ T cells (30, 51) and 436 
secretion of the pro-inflammatory chemokine macrophage inflammatory protein (MIP)-437 
1β which has been shown to be secreted by CD4+ T cells (30) in response to 438 
stimulation by HCMV protein peptide pools.  CMV specific CD4+ T cells were identified 439 
as CD40L+ and CD69high compared to the background unstimulated population (52) and 440 
the proportion of CD107a or MIP-1β positive cells measured, a representative analysis 441 
of gB specific CD4+ T cell response is shown (Fig. 3A).  The results of CD107a 442 
expression for n=12 donors (Fig. 3B) and MIP-1β secretion for n=9 donors (Fig. 3C) by 443 
CMV specific CD4+ T cells for each of the 6 HCMV ORFs are summarised.  CD4+ T 444 
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cells stimulated directly ex vivo are capable of degranulation as shown by the proportion 445 
of antigen specific CD107a expressing cells present (Fig. 3B).  The ability of gB specific 446 
CD4+ T cells to produce cytotoxic function has previously been established (16, 47, 53), 447 
however this analysis indicates that CD4+ T cells specific to the other 5 proteins also 448 
possess this capacity.  All the donors examined expressed CD107a in CMV specific 449 
CD4+ T cells in response to at least one of the six HCMV proteins.  A proportion of 450 
CD4+ T cells specific to all 6 HCMV proteins studied were also able to secrete MIP-1β 451 
following stimulation extending previous reports of this phenomenon in pp65 specific 452 
CD4+ T cells (30). 453 
 454 
The memory phenotype of CMV specific CD4+ T cells in previous studies has been 455 
shown to be a differentiated memory phenotype, characterised by the downregulation of 456 
the co-stimulatory molecule CD27 (21, 24) and re-expression of CD45RA (11, 21, 24), 457 
and the loss of CD28 and expression of CD57 (20, 22, 27, 30).  To assess whether the 458 
memory T cell phenotype differs between the 6 HCMV protein specific CD4+ T cell 459 
populations the proportion of antigen specific cells with one of 4 memory populations 460 
defined by expression of CD27 and CD45RA molecules, and the proportion that have 461 
lost expression of CD28 and upregulated CD57 expression was measured.   462 
 463 
Antigen specific CD4+ T cells were again identified by upregulation of CD69 and CD40L 464 
(52), an example of the phenotype of the total CD4+ T cell population and an exemplar 465 
HCMV specific population from one donor is shown (Fig. 4A).   The proportion of HCMV 466 
protein specific CD4+ T cells with the different memory populations are compared in 467 
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summary graphs for CD27- CD45RA+; TEMRA (EMRA, Effector Memory CD45RA 468 
expressing) (Fig. 4B), CD27+ CD45RA+; TNL (NL, naive like) (Fig. 4C), CD27- CD45RA-469 
; TEM (EM, Effector Memory) (Fig. 4D), CD27+ CD45RA-; TCM (CM, Central Memory) 470 
(Fig. 4E), CD28- CD57+, Highly Differentiated Memory cells (Fig. 4F) and CD28+ 471 
CD57-; less differentiated Memory cells (Fig. 4G).  Additionally the proportion of total 472 
CD4+ T cells from age-matched CMV sero-negative donors for the 4 memory 473 
populations defined by CD27 and CD45RA expression is also shown (Fig. 4B – E).  The 474 
comparison of the CMV sero-negative and positive total CD4+ populations for each of 475 
the 4 memory populations revealed that CMV sero-positive donors have significantly 476 
more TCM (Fig. 4E), TEM (Fig. 4D) and TEMRA (Fig. 4B) differentiated CD4+ T cells (Mann 477 
Whitney U test, significant results p<0.01 ## and p<0.0001 #### are shown).   This 478 
confirms previous observations of the impact of CMV infection on the phenotype of 479 
CD4+ T cells (summarised in (37)).  The distribution of the CMV sero-positive donors 480 
CD4+ T cell responses to the 6 HCMV proteins and total CD4+ T cells for the 6 different 481 
memory phenotype populations was analysed using a non-parametric Kruskall-Wallis 1-482 
way ANOVA test (results are shown Fig. 4B – 4G).  Where there was significant 483 
variance a Wilcoxon rank pairs test was used as a post-test to pairwise compare the 484 
proportion of the antigen specific population expressing each phenotype with the total 485 
CD4+ population and the other HCMV proteins for each donor, significant differences of 486 
p≤0.01 (to account for repeated measures) between the populations are indicated on 487 
the graphs.  The analysis of memory phenotypes showed that CMV protein specific 488 
CD4+ T cells have a significant decrease in the less differentiated memory phenotypes 489 
compared to the total CD4+ population (Fig. 4C and 4E).  There was a corresponding 490 
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significant enrichment in the differentiated effector memory sub-populations for all 6 491 
HCMV protein specific populations (Fig. 4B).  Comparison of the proportion of CMV 492 
specific CD4+ T cells exhibiting different memory population phenotypes revealed that 493 
US3 specific CD4+ T cells had a significantly greater proportion of TEMRA cells compared 494 
to gB and IE2 (Fig. 4B; gB specific CD4+ T cells were enriched in the TCM population 495 
compared to  4 other HCMV proteins (Fig. 4E).   There was no significant changes in 496 
the proportion of CMV specific CD4+ T cells with a highly differentiated (Fig. 4F) or 497 
undifferentiated (Fig. 4G) memory cell populations, although the antigen specific 498 
populations were enriched for the highly differentiated population compared to the total 499 
CD4 T cells.     500 
 501 
The HCMV specific CD4+ T cells produce poly-functional responses to virally 502 
infected cells 503 
 504 
The use of CMV viral lysate or overlapping peptide pools to characterise CD4+ T cell 505 
responses to CMV does not allow the effect of  CMV encoded immune evasion 506 
molecules during infection, particularly the downregulation  of MHC Class II expression 507 
on antigen presenting cells (54).  To assess the CD4+ T cell response in the presence 508 
of viral encoded immune evasion molecules we used an in vitro infection of autologous 509 
dendritic cells using a clinical isolate of CMV method.   Autologous dendritic cells 510 
derived from individual donor monocytes (moDCs) were infected with a UL32 GFP 511 
tagged HCMV strain TB40\E (TB40\e-UL32-GFP).  The CMV infected moDCs were 512 
incubated for 7 days prior to co-incubation with autologous CD4+ T cells overnight and 513 
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measuring functional responses in responding CD4+ T cells by flow cytometry.  In total 514 
the functional responses of 12 donors to virus infected moDCs were analysed, the size 515 
of the HCMV specific response (identified by the co-upregulation of the activation 516 
markers CD40L and 4-1BB) above background by the CD4+ T cells and the fraction of 517 
those cells producing each of the 4 individual functional markers (MIP-1β, Granzymes A 518 
& B, IFNγ and CD107a) or none were compared (Fig. 5A).  The breakdown of the 519 
antigen specific response equates to 49.2% (±8.9 S.E.M.) of responding CD4+ T cells 520 
not producing any of these effector markers, of the remaining antigen specific CD4+ T 521 
cells 41.7% (±8.6% S.E.M.) produced IFNγ and 16.3% (±4.0% S.E.M.) expressed 522 
CD107a, with a minority of virus specific CD4+ T cells producing MIP-1β (4.9% ± 2.4 523 
S.E.M.) or Granzymes A and B (4.6% ±2.1 S.E.M.).  The poly-functionality of the virus 524 
specific CD4+ T cell response in 12 donors was assessed and the mean proportion of 525 
virus specific cells producing 1 or more functions was compared (Fig. 5B), 14.6% of 526 
responding cells produced 2, 3 or 4 functions, and a further 36.2% produced 1 527 
functional response.  The proportion of virus specific CD4+ T cells responding within the 528 
16 different categories created by combinations of the 4 functional markers for all 12 529 
donors is shown (Fig. 5C), this breakdown analysis of the HCMV specific CD4+ T cells 530 
that produce one or more functional response (comprising 50.8% of the activated cells 531 
response) confirms the dominance of IFNγ production alone (28.8% ± 5.3 S.E.M.) and 532 
in combination with CD107a expression (7.9% ± 2.3 S.E.M.).  The other notable 533 
populations are expression of CD107a only (4.8% ± 1.3 S.E.M, the population 534 
producing IFNγ and MIP-1β (2.2% ± 1.1 S.E.M.), the Granzymes A and B only 535 
producing cells (2.1% ± S.E.M.) and triple functional cells producing IFNγ, MIP-1β and 536 
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expressing CD107a (1.8% ± 1.2 S.E.M.). Phenotype analysis of the virus specific CD4+ 537 
T cells reveals an undifferentiated (CD28+ CD57-, 58.9% ± 7.5 S.E.M.) effector memory 538 
(CD27- CD45RA-, 35.6% ± 2.9 S.E.M.) population (Fig. 5D) similar to that seen in 539 
peptide stimulated cells (Fig. 4). 540 
 541 
In 3 donors we compared the CD4+ T cell response to TB40\e-UL32-GFP infected cells 542 
with moDCs infected with an identical MOI of UV inactivated virus.   The size of the 543 
corrected antigen specific response measured by upregulation of CD40L and 4-1BB is 544 
shown for each donor (Fig. 5E), this comparison shows that for all three donors the 545 
response to live virus was greater than for the UV inactivated virus.  There was however 546 
a notable CD4+ T cell response to the UV virus treated cells, suggesting that inactive 547 
viral particle proteins were still being presented by the moDCs 7 days after the initial 548 
infection.  We confirmed that the UV treatment of the virus was inactive by fluorescent 549 
microscope analysis of GFP expression in the moDCs (an example from donor CMV320 550 
is shown Fig. 5F), which clearly shows that the late gene UL32 which is tagged with 551 
GFP in the HCMV viral strain used for these studies is only expressed in the infected 552 
cells at day 7 post infection and is not observed in the UV inactivated virus treated 553 
moDCs. 554 
 555 
HCMV specific CD4+ T cells control the dissemination of virus in vitro 556 
 557 
The evidence that live cytomegalovirus infection was able to stimulate functional CD4+ 558 
T cell responses to a greater extent that UV-inactivated virus led to an investigation of 559 
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whether these CMV specific CD4+ T cells could directly target an active lytic infection.  560 
We have previously established a viral dissemination assay for CD8+ T cells (48) using 561 
autologous fibroblasts infected with a low MOI of TB40\e-UL32-GFP strain to measure 562 
the ability of the CD8+ T cell subset to abrogate viral spread.  To be able to interrogate 563 
the role of CMV specific CD4+ T cells in the same way required an adaptation of this 564 
experimental model because fibroblasts do not constitutively express MHC Class II 565 
molecules (55).  Autologous in vitro differentiated moDCs was chosen as these cells 566 
both constitutively express MHC Class II (55) and are permissive for lytic CMV infection 567 
(56).  Dendritic cells derived from each donor were infected with TB40\e-UL32-GFP at a 568 
low MOI, after 7 days culture CD4+ T cells isolated directly ex-vivo were added at 569 
effector (CD4+ T cells) to target (moDCs) (E:T) ratios of 1.2:1, 0.6:1 and 0.3:1 in 570 
triplicate.  The CD4+ T cells were co-incubated with the infected moDCs for a further 7 571 
days and then indicator fibroblasts were added, to be infected by virus released from 572 
any remaining infected dendritic cells, and co-incubated for 14 – 21 days prior to 573 
analysis by flowcytometry for GFP expressing (virus infected) fibroblasts. 574 
 575 
We have measured viral dissemination in 5 HCMV sero-positive donors and 1 HCMV 576 
sero-negative donor as a control.    The dissemination of TB40\e-UL32-GFP to 577 
fibroblast cells was assessed by fluorescent microscopy and flow cytometry, an 578 
example from donor CMV320 is illustrated following 14 days incubation with indicator 579 
fibroblasts (Fig. 6A), this clearly shows a lack of GFP expression in the uninfected wells 580 
and the wells treated with CD4+ T cells at all 3 E:T ratios compared to that observed in 581 
the infected only control.    The results from the flow cytometry analysis for 5 sero-582 
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positive donors (Fig. 5B – 5F) and 1 sero-negative donor (Fig. 5G) are summarised, the 583 
data for each treatment was corrected for background and then expressed as a 584 
proportion of the Infected control (which is therefore set at 100% for all 6 donors).  The 585 
graphs from all 5 HCMV sero-positive donors show that the addition of CD4+ T cells 586 
stopped the dissemination of HCMV into the fibroblast layer, the results from CMV425 587 
(Fig. 5G) the sero-negative donor clearly demonstrate that this is the action of CMV 588 
specific CD4+ T cells as the proportion of fibroblasts infected with the GFP tagged virus 589 
was observed at similar levels to the infected control.  The evidence from this functional 590 
assay together with the poly-functional responses described in Fig. 5 clearly shows that 591 
resting HCMV specific CD4+ T cells isolated directly ex-vivo have direct anti-viral 592 
activity producing inflammatory cytokines and cytotoxic responses which enable these 593 
cells to prevent viral dissemination.     594 
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Discussion 595 
 596 
Within ageing, studies have implicated CMV as being associated with increased risk of 597 
all-cause mortality in older people (37) and causing detrimental changes to the immune 598 
response (27-29). The paradox with the association of CMV sero-positivity with the loss 599 
of immune function in older people is that overt CMV disease from reactivation or new 600 
infections is not observed, however there is an increase in detectable virus in urine in 601 
the old (44).  This strongly suggests that the immune response to HCMV itself retains 602 
sufficient functionality within the older immunocompetent population, but that 603 
immunomodulation as a consequence of lifelong carriage of HCMV may alter the 604 
immune response (57).   Secretion of the immunomodulatory cytokine IL-10 (58) by 605 
CMV specific CD4+ T cells is a candidate for mediating immunomodulation of the CMV 606 
specific T cell response during ageing.  Previously we have identified populations of 607 
CD4+ T cells specific for the HCMV proteins UL138 and LUNA that secrete IL-10 (47).   608 
Others have observed secretion of IL-10 by CMV specific CD4+ T cells in response to 609 
stimulation by pp65 and IE1 and they demonstrated that frequent exposure to CMV 610 
antigens drove the generation of an iTreg CD4+ T cell population specific to HCMV (50).  611 
We hypothesised that older CMV sero-positive donors may have increased numbers of 612 
CD4+ T cells secreting IL-10 following CMV antigen stimulation due to longer periods of 613 
exposure to viral antigens and that this subset of CMV specific CD4+ T cells may inhibit 614 
efficient recognition of the virus by IFNγ secreting CMV specific CD4+ T cells.   615 
 616 
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We did not see any influence of donor age on the magnitude of the total CMV specific 617 
CD4+ T cell IFNγ or IL-10 responses to gB, pp65, pp71 and IE2 stimulations.  There 618 
was a significant decline in the IE1 IL-10 specific CD4+ T cell response in older donors, 619 
but the relationship of the magnitude of the total IFNγ and IL-10 responses to all 6 620 
proteins for each donor was not affected by donor age.  We have therefore 621 
demonstrated that a proportion of CD4+ T cells specific to the 6 different HCMV proteins 622 
examined here produced IL-10 but overall this response is limited compared to the IFNγ 623 
response observed.   However, we did observe some donors (approximately 1 in 6) 624 
within the cohort who did have an equal or higher frequency IL-10 sfu/million response 625 
compared to the IFNγ response to 3 or more of the CMV protein responses examined.  626 
Overall there was no alteration in the balance of IL-10 and IFNγ secretion with 627 
increasing donor age and putative increased length of viral carriage and exposure to 628 
viral antigens in this study.  It would be interesting to examine whether donors in a 629 
suitably sized cohort with an IL-10 bias in the CD4+ T cell response to CMV antigens 630 
differ in other aspects of their CMV immune response, such as CMV IgG titres or viral 631 
carriage.   632 
 633 
The observations from this cohort regarding the impact of donor age on CMV specific 634 
CD4+ T cell responses are in contrast to some other studies which have shown an 635 
accumulation of IFNγ secreting CD4+ T cells in older donors (19, 21, 22).  These 636 
studies used viral lysate to stimulate HCMV specific CD4+ T cells rather than focussing 637 
on responses to particular HCMV proteins and intracellular flow cytometry to measure 638 
the IFNγ response.   The current study used fluorospot assays to measure IFNγ 639 
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production by CD4+ T cells; Fluorospot is a development of enzyme-linked immunospot 640 
(ELISPOT) assays which enables measurement of multiple cytokines simultaneously 641 
(59).  Experience from our own studies and other groups suggests that ELISPOT is 642 
more sensitive for detecting T cell responses to HCMV antigens (60), so the contrasting 643 
observations in this study compared to previously published work are not explained by 644 
the use of different techniques to measure IFNγ responses.  The studies demonstrating 645 
increased frequency of CMV specific CD4+ T cells in older donors (19, 21, 22) did not 646 
investigate the absolute size of the T cell compartment in peripheral blood.  This is 647 
important as the increased percentage measured in these studies may only equate to 648 
the same numbers of IFNγ producing CD4+ T cells if the total CD4+ T cell compartment 649 
size decreases for instance.   It is therefore difficult to compare the conclusions from 650 
studies where the methods of reporting results differ between frequency and 651 
percentages, particularly when the information required for interpreting the presented 652 
percentage data are absent.   It has been previously observed that donor cohorts from 653 
different geographical locations, e.g. a study of older Sicilians with 70% CMV sero-654 
positivity (61), did not show an accumulation of CMV specific CD8+ T cells in the older 655 
donor group compared to young donors.  Understanding that HCMV infection does not 656 
have the same effect on all older donor cohorts is important when interpreting studies 657 
which propose medical intervention in CMV sero-positive older people as necessary to 658 
improve immune response and promote a healthy ageing phenotype.    659 
 660 
It is becoming increasingly clear in both CMV infection (26, 31, 53) and other viral 661 
infections, e.g. influenza, West Nile virus, rotavirus and sendai virus (reviewed in (62)) 662 
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that CD4+ T cells can exhibit direct effector functions, including cytotoxicity and the 663 
secretion of pro-inflammatory effector molecules that help to control or resolve viral 664 
infections.  We saw that CD4+ T cells specific to all 6 HCMV proteins upregulated 665 
expression of CD107a, a marker of degranulation used as a surrogate indicator of 666 
potential cytotoxic activity (30), and produced the pro-inflammatory chemokine MIP-1β.  667 
Our observations on the memory phenotype of CMV specific CD4+ T cells do confirm 668 
previous studies using pp65 peptides and viral lysate stimulation which have described 669 
CMV specific CD4+ T cells as having an effector memory phenotype (19, 21, 30).    The 670 
use of  in vitro stimulation of CD4+ T cells with HCMV peptide pools or viral lysate 671 
allows the determination of T cell effector functions but this is in the absence of immune 672 
evasion molecules expressed by CMV during its lytic lifecycle.  Examining CMV specific 673 
T cell responses in the absence of viral immunomodulation is not representative of the 674 
situation during CMV infection or reactivation in the host (57).  CMV encoded proteins 675 
target many aspects of the immune response including evading natural killer cell 676 
responses, the interferon response and perturbation of immunomodulatory pathways 677 
(reviewed in (54).  Pertinent to affecting host CD4+ T cell effector responses, the 678 
proteins encoded by CMV US3 (63) and US2 (64) interfere with MHC Class II 679 
presentation at the cell surface, UL82 which encodes the phosphoprotein pp65 can 680 
mediate destruction of HLA-DR molecules (65), and loss of MHC Class II expression by 681 
CMV infected dendritic cells (66, 67).  The combined effect of these immune evasion 682 
and modulatory proteins in an active infection or reactivation event by CMV in the host 683 
could lead to very different effector behaviour by CMV specific CD4+ T cells than 684 
observed in response to isolated viral proteins.  This problem has been addressed to an 685 
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extent in the murine model with MCMV infection, a recent paper using novel epitope 686 
Class II restricted tetramers in vivo have observed direct killing of infected cells (68).  687 
With respect to HCMV infections, Sinzger et al have shown that IE1 specific CD4+ T cell 688 
clones are able to produce IFNγ in response to stimulation by TB40\E infected 689 
macrophages which have downregulated MHC Class II expression (69).  690 
 691 
We used an experimental model of lytic infection in vitro to measure the effector 692 
functions of CD4+ T cells isolated directly ex vivo in response to HCMV infected 693 
monocyte derived dendritic cells.  The predominant effector function produced was IFNγ 694 
followed by CD107a expression, low levels of the cytolytic enzymes Granzymes A & B 695 
and MIP-1β were also detected.  The    poly-functional CD4+ T cell responses observed 696 
are important as they have been shown to be better effector cells (51) and reduced 697 
frequencies of poly-functional CMV specific CD4+ T cells are associated with the 698 
occurrence of congenital CMV infections (70).   However these assays still just measure 699 
effector mechanisms and does not give any indication if the T cells could mediate direct 700 
anti-viral activity.  In order to measure the effectiveness of these CMV specific CD4+ T 701 
cells we performed a viral dissemination assay using the non-attenuated clinical strain 702 
TB40\e-UL32-GFP.  We performed the assay in 5 HCMV sero-positive donors and 703 
clearly observed the CD4+ T cells preventing viral dissemination from the virus infected 704 
dendritic cells.   By performing the assay with a CMV sero-negative donor we confirmed 705 
that this was a CMV specific CD4+ T cell effect, as there was no control of viral 706 
dissemination in the presence of non-specific CD4+ T cells.  This assay convincingly 707 
shows that CD4+ T cells can respond directly to CMV infected cells probably using both 708 
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cytokine and cytotoxicity mechanisms observed in the poly-functional flow cytometry 709 
experiments.  The ability of CMV specific CD4+ T cells to control viral dissemination is 710 
inspite of the large array of immune evasion mechanisms encoded by the virus, and 711 
confirms the observations made in vivo in the murine model (68) and previously in 712 
infected macrophages in HCMV in vitro models (69).  Further interrogation of the CMV 713 
specific CD4+ T cell response using this in vitro model will be able to determine whether 714 
cytokines or cytotoxicity produced by CD4+ T cells are more important in resolving CMV 715 
infection or re-activation in the host. 716 
 717 
In summary, we have shown that the CD4+ T cell response to lytic HCMV antigens and 718 
infection is not obviously attenuated in older donors.  CD4+ T cells specific to HCMV 719 
have cytotoxic capability and secrete MIP-1β and IFNγ which are known to be essential 720 
to control viral replication (13, 20, 70) and can control viral dissemination in vitro.  721 
Previous studies focussing solely on T cell responses to limited HCMV ORF encoded 722 
proteins or inactive viral lysate in the ageing immune response (71) may have resulted 723 
in too narrow a perspective on understanding the aetiology of the CMV infection and 724 
diseases in healthy older people.  In order to understand why older donors may 725 
reactivate virus more frequently compared to younger donors (44) will require further 726 
study of CD4+ T cell responses in the context of viral infection models.  By interrogating 727 
the immune response to the entire HCMV proteome expressed during both lytic and 728 
latent infection using direct anti-viral assays instead of relying on responses to isolated 729 
peptide stimulation will help to identify whether the HCMV specific T cell response is 730 
impaired in ageing or immunocompromised patients.  This will also enable the 731 
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development of effective immunotherapeutic treatments for HCMV infection and widen 732 
our knowledge of the functional capacity of CD4+ T cells in response to virus infection.733 
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FIGURE LEGENDS 991 
  992 
FIG 1 – The magnitude of IFNγ secreting CD4+ T cell responses to 6 HCMV 993 
proteins is maintained with increasing donor age.   994 
The frequency of the CD4+ T cell responses to 11 HCMV protein peptide pools was 995 
determined in 18 donors by IFNγ ELISPOT, the number of donors with a positive 996 
response (<100 spot forming units/million cells (sfu/million) after background count 997 
correction) to each protein is tallied and ranked (A).  The IFNγ secreting CD4+ T cell 998 
response to 6 HCMV proteins: pp65, gB, IE2, pp71, US3 and IE1 was measured in a 999 
cohort of 84 HCMV sero-positive and 13 sero-negative donors using an IFNγ Fluorospot 1000 
technique.  The results were converted to sfu/million T cells with background counts 1001 
subtracted,  the response to each protein and the positive control by the entire cohort is 1002 
summarised (B) with both CMV seropositive donors (dark grey data points) and CMV 1003 
seronegative donors (white data points) illustrated.  The distribution of the CMV 1004 
seronegative donor’s responses to each HCMV protein peptide pool  and the response 1005 
to the positive control determined the positive HCMV peptide pool response threshold 1006 
cut-off of 100 sfu/million (dashed line), the proportion of donors responding above the 1007 
threshold to each protein and the positive control are shown.  The proportion of the 84 1008 
sero-positive donors producing a positive response to 1 or more of the 6 HCMV protein 1009 
peptide pools is summarised (C).  Within the sero-positive cohort the total IFNγ 1010 
response to all six proteins is shown as a correlation of donor age with the size of the 1011 
donor response (D) and for each individual protein; pp65 (E), IE1 (F), gB (G), IE2 (H), 1012 
pp71 (I) and US3 (J).   The correlation of the CMV proteins response with age was 1013 
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analysed using Spearman rank correlation (Spearman rs with 95% Confidence Intervals 1014 
(CI) and p value are indicated on each graph); a line of best fit (solid) and the 95% CI 1015 
(dotted lines) are also shown; due to the repeated analyses performed results were only 1016 
considered significant if p≤0.01. 1017 
 1018 
FIG 2 – The HCMV specific CD4+ T cell response is predominantly Th1. 1019 
The frequency of the IL-10 secreting CD4+ T cells in response to 6 HCMV proteins and 1020 
positive control stimulation in 59 sero-positive and 8 sero-negative donors is shown.  IL-1021 
10 secretion was measured using a Fluorospot method, the results were converted to 1022 
spot forming units/million cells (sfu/million) with background counts subtracted,  the 1023 
response to each protein and the positive control by the entire cohort is summarised (A) 1024 
with both CMV sero-positive donors (dark grey data points) and CMV sero-negative 1025 
donors (white data points) illustrated.  The distribution of the CMV sero-negative donor’s 1026 
responses to each protein and the response to the positive control determined the 1027 
positive HCMV protein response threshold cut-off of 50 sfu/million (dashed line), the 1028 
proportion of donors responding above the threshold to each protein and the positive 1029 
control are indicated (ranging from 44% sero-positive donors responding to pp71 and 1030 
US3 stimulation to 15% responding to gB stimulation).  The frequency of sero-positive 1031 
donors producing a positive response to none, 1 or more of the 6 proteins is 1032 
summarised (B).  The frequency of CD4+ T cells that secrete IFNγ or IL-10 in response 1033 
to 6 HCMV proteins were measured simultaneously using a dual IFNγ/IL-10 fluorospot 1034 
assay.  The response to 6 HCMV proteins; pp65 (UL83) (C), IE1 (UL123) (D), gB 1035 
(UL55) (E), IE2 (UL122) (F), pp71 (UL82) (G) and US3 (H) are summarised for the 59 1036 
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donors arranged along the x-axis in age order (donor ages 23 – 74 years).  For each 1037 
HCMV protein graph, only donors with positive responses above the threshold for either 1038 
IFNγ (> 100 sfu/million) [dark grey bars] or IL-10 (> 50 sfu/million) [clear bars] are 1039 
shown; dual secreting cells are also indicated when present [hatched yellow bars].  1040 
There was no significant change in the magnitude of the IFNγ response with donor age 1041 
measured using Spearman rank correlation, there was a significant decrease in IE1 1042 
specific cells secreting IL-10 with donors age (Spearman rs= -0.4185, (Confidence 1043 
Interval: -0.6595, -0.0994), p=0.01 **, n=37), there was no significant changes in IL-10 1044 
secretion with donor age for the other 5 proteins.   1045 
 1046 
FIG 3 – A proportion of HCMV specific CD4+ T cells have cytotoxic capacity and 1047 
can secrete MIP-1β 1048 
PBMC were stimulated overnight with HCMV peptide pools in the presence of αCD107a 1049 
antibody, Brefeldin A and Monensin to measure degranulation and production of MIP-1050 
1β.  Identification of HCMV specific CD4+ T cell responses was as described in the 1051 
methods; antigen specific CD4+ populations were identified as CD40L+ and CD69 high 1052 
compared to the background unstimulated population and the proportion of antigen 1053 
specific CD4+ T cells upregulating CD107a or producing MIP-1β was measured (a 1054 
representative example of the response to gB is shown (A)).  The results from all the 1055 
donors examined are summarised for CD107a expression n=12 (B) and MIP-1β 1056 
production n=9 (C).  There were no significant differences in the proportion of CMV 1057 
protein specific CD4+ T cells upregulating CD107a or producing MIP-1β (Kruskall-Wallis 1058 
1-way ANOVA with post-hoc Dunn’s multiple comparisons).   1059 
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 1060 
FIG 4 – HCMV specific CD4+ T cells have a predominantly effector memory 1061 
phenotype and are not highly differentiated. 1062 
PBMC were stimulated overnight with HCMV protein peptide pools in the presence of 1063 
Brefeldin A.  HCMV specific CD4+ T cell responses were identified by expression of 1064 
CD40L and CD69 above background and 4 memory phenotype sub-sets defined 1065 
according to the expression of CD27 and CD45RA: TNL (NL; Naïve like) 1066 
CD27+CD45RA+, TCM (CM; Central Memory) CD27+CD45RA-, TEM (EM; Effector 1067 
Memory) CD27-CD45RA- and TEMRA (EMRA; Effector Memory CD45RA+) CD27-1068 
CD45RA+, and 2 memory differentiation phenotype populations defined according to 1069 
the expression of CD57 and CD28: undifferentiated (CD28+ CD57-) and highly 1070 
differentiated (CD28- CD57+) were measured.  A representative example illustrating the 1071 
expression of these six phenotypes in total CD4+ and pp65 specific T cells is shown (A).  1072 
The results are summarised for each phenotype population of interest comparing the 1073 
responses to 6 HCMV proteins with the total CD4+ T cell population for n=15 CMV sero-1074 
positive donors and the total CD4+ T cell population for n=15 age-matched CMV sero-1075 
negative donors for the following populations; TEMRA (B), TNL(C), TEM (D), TCM (E).  The 1076 
responses to 6 HCMV proteins with the total T cell population for n=15 CMV sero-1077 
positive donors only are summarised for these populations; CD28- CD57+ (F) and 1078 
CD28+ CD57- (G).  A non-parametric Kruskall-Wallis 1-way ANOVA test was performed 1079 
for the CMV sero-positive donors for each memory population (results indicated on each 1080 
graph).  Where significant variation was observed a Wilcoxon matched-pairs post-test 1081 
was performed to compare the different proportion of CMV specific CD4+ T cells to total 1082 
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CD4+ T cells and each of the other CMV specific protein populations;  significant results 1083 
for each individual comparison are indicated on the appropriate graph ( ** p<0.01; *** 1084 
p<0.001).  Lastly the CMV sero-positive donors total CD4+ T cell CD27 and CD45RA 1085 
defined memory populations were compared to the CMV sero-negative donors using a 1086 
Mann Whitney U test; significant results are indicated on the appropriate graph (## 1087 
p<0.01; #### p<0.0001). 1088 
 1089 
FIG 5 – The HCMV specific CD4+ T cell response to HCMV infected cells is poly-1090 
functional.  1091 
Monocyte derived dendritic cells (moDCs) were prepared from each donor and then 1092 
mock or lytically infected with HCMV strain TB40\e UL32-GFP at an MOI 0.1 for 7 days.  1093 
Autologous CD4+ T cells were incubated overnight with either uninfected, HCMV 1094 
infected or UV irradiated HCMV infected moDCs in the presence of αCD107a antibody, 1095 
monensin and brefeldin A.  CD4+ T cells were then stained with a poly-functional flow 1096 
cytometry antibody panel, acquired and analysed.  Virus specific CD4+ T cells were 1097 
identified by the upregulation of CD40L and 4-1BB above background.  The total 1098 
specific response to CMV virus and the proportion of the specific response composed of 1099 
MIP-1β, Granzymes A and B, CD107a and IFNγ production or no functional marker in 1100 
n=12 donors are shown (A).  The mean proportion of virus specific CD4+ T cells 1101 
generating poly-functional responses from all donors is summarised as a pie chart 1102 
indicating the proportion of HCMV specific CD4+ T cells producing 4, 3, 2, 1 or no 1103 
functions (B).  The composition of the HCMV specific CD4+ T cell response as a 1104 
proportion of antigen specific population for all donors is illustrated (C).  The proportion 1105 
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of virus specific cells expressing different memory cell phenotype markers (CD27, 1106 
CD45RA, CD28 and CD57) is shown (D).  A direct comparison of the size of the specific 1107 
T cell response to live virus vs UV inactivated response in 3 donors is shown (E).     A 1108 
representative example of UL32 (late gene) tagged GFP expression in moDCs infected 1109 
with live virus vs UV inactivated virus (F) indicating GFP expression in live virus infected 1110 
moDCs only.   1111 
 1112 
FIG 6 – HCMV specific CD4+ T cells are able to prevent dissemination of virus in 1113 
vitro. 1114 
Monocyte derived dendritic cells (moDCs) were prepared from each donor and then 1115 
mock or lytically infected with HCMV strain TB40\e-UL32-GFP at MOI 0.007 for 7 days.  1116 
CD4+ T cells were co-incubated with the infected moDCs at a range of E:T ratios for a 1117 
further 7 days.  Indicator fibroblasts were then added to the post CD4+ T cell treated 1118 
infected moDCs for up to 28 days and then the percentage of fibroblasts expressing 1119 
GFP tagged virus were measured by flow cytometry. Representative dot plots showing 1120 
the GFP expression from one well of triplicates and a corresponding fluorescent 1121 
microscope image are shown (A).  The bar charts from 5 HCMV sero-positives (B – F) 1122 
and 1 sero-negative donor (G) summarise the percentage of TB40\e-UL32-GFP 1123 
expressing fibroblasts corrected for background and as a percentage of the infected 1124 
only control. 1125 
 1126 
 1127 
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